Investor Presentaiton
Darovasertib + Crizotinib Combination Clinical Summary in MUM
Highly Differentiated Clinical Efficacy & AE Profile Observed***
Darovasertib + Crizotinib
Cabozantinib Mono /
Crizotinib Mono
Selumetinib + DTIC
Target/Mechanism
PKC + CMET
CMET
MEK + Chemotherapy
Study Name(s)
NCT03947385
A091201^/NCT05063058^^^^
NCT01974752^^^
NCT02626962##
Population
1L/2L/3L+ MUM (n=63)
1L+ MUM (n=31) /
1L (n=6) 2L (n=1) MUM
1L+ MUM (n=97)
1L MUM (n=52)
Patient Selection
NA
NA/MET Overexpression
NA
Ipi + Nivo
CTLA4 + PD1
ΝΑ
Tebentafusp
HLA-A2-0201 Bi-Specific
IMCgp100-102#
2L+ MUM (n=127)
HLA-A2-positive
Oral Tablets
Oral Capsules
33%
51.6% / NA
23% ^^/NA
Drug Form
Tolerability (Grade ≥3
Drug-Related AE)
% of Patients with
Tumor Shrinkage
Confirmed ORR%
(by RECIST 1.1)
Median PFS
First-Line = 95% / Any-Line = 92% /
Hepatic Only 100%*
=
First-Line = 45% / Any-Line = 30% /
Hepatic Only = 35%*
First-Line: ~7 months / Any-Line: ~7
months / Hepatic-Only: 11 months*
0% / 0%
2 months/ NA
+ Cross-trial comparisons are not based on head-to-head studies and are presented for informational purposes; no direct comparisons are being made
++ ESMO 2022: F. Dimitriou, et.al: IPI + Nivo Combo in HLA-A2-0201 MUM reports ~6% ORR (2 PRS out of 33 patients)
* IDEAYA Data: preliminary analysis of unlocked database as of 03/08/2023 by investigator review, and C1D1 cutoff as of 9/22/2022
11.5%
3%
(not confirmed ORR)
2.8 months
3 months
4.7%
2.8 months
# Based on Immunocore reported 2L+ study data (to reflect comparative patient population) and by independent review and ORR% was with confirmed PRs; ## ASCO 2021, J. Piulats, et. Al, Ipi = ipilimumab, nivo = nivolumab, ORR% did not require PR/CR confirmation
^ Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201); Clin Cancer Res 2020;26:804-11
Oral Capsules + chemo
IV infusion
IV Infusion (Weekly)
63%
(All Cause)
58%
46.5%
35% ^^
27%^
44%
^^
16
^^ Estimated from Waterfall plot
^^^ Journal of Clinical Oncology, Carjaval, et. al, 2018; 1232-1239;1 European Journal of Cancer, Leyraz, et. al, 2022; 146-155
ΑΛΛΑ
IDEA A
BIOSCIENCESView entire presentation